

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4809775

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	INDIVIOR INC.	12/12/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	INDIVIOR UK LIMITED	
<b>Street Address:</b>	103-105 BATH ROAD	
<b>City:</b>	SLOUGH, BERKSHIRE	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	SL1 3UH	
<b>PROPERTY NUMBERS Total: 3</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	14576357	
<b>Application Number:</b>	14882857	
<b>Application Number:</b>	15005502	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	617-542-6000	
<b>Email:</b>	cdipasupil@mintz.com, ipdocketingBOS@mintz.com	
<b>Correspondent Name:</b>	MINTZ LEVIN	
<b>Address Line 1:</b>	ONE FINANCIAL CENTER	
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02111	
<b>ATTORNEY DOCKET NUMBER:</b>	48500-532001US/C01U/C02US	
<b>NAME OF SUBMITTER:</b>	EDWARD D. GRIEFF	
<b>SIGNATURE:</b>	/Edward D. Grieff/	
<b>DATE SIGNED:</b>	02/05/2018	
<b>Total Attachments: 3</b>		
source=048500-532-Assignment#page1.tif		
source=048500-532-Assignment#page2.tif		
source=048500-532-Assignment#page3.tif		

## ASSIGNMENT

Indivior Inc. ("Assignor"), having a place of business at 10710 Midlothian Turnpike, Richmond, VA 24335, USA, is the owner of the entire right, title, and interest in the patents and applications listed in Appendix A.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby:

Assigns, transfers, and conveys, to Indivior UK Limited ("Assignee"), having a place of business at 103-105 Bath Road, Slough, Berkshire, SL1 3UH, United Kingdom, the entire right, title, and interest in and to:

- (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the patents and patent applications listed in Appendix A, implicitly or explicitly;
- (b) the patents and patent applications listed in Appendix A, the right to claim priority to the patents and patent applications listed in Appendix A, all applications based in whole or in part upon the patents and patent applications listed in Appendix A, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the patents and patent applications listed in Appendix A;
- (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

ASSIGNMENT

Page 2 of 3

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patents, or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent applications or intellectual property described in paragraph 1 of this Assignment and the enforcement of patents or other rights resulting from such patent applications or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside my signature.

Signature: Nancy DuVal Date: 12/12/2017

Name: Nancy DuVal

Title: General Counsel, Corporate

Authorized Signatory

Indivior Inc.

Signed and hereby accepted on behalf of the Assignee:

Craig Svoboda Craig Svoboda 12/12/2017  
Name Title Date  
Legal Director - Intellectual Property

**Appendix A**

<b>Country</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Title</b>
Canada	2875384	19-Dec-2014		INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
Europe	14825055.8	19-Dec-2014		INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
Patent Cooperation Treaty	PCT/US2014/071371	19-Dec-2014		INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
United States of America	14/576,357	19-Dec-2014	9,192,570	INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
United States of America	14/882,857	14-Oct-2015	9,289,425	INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
United States of America	15/005,502	25-Jan-2016		INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
United States of America	61/918,802	20-Dec-2013		INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME